JP2019524723A - 皮膚および/または毛の修復のための5−ヒドロキシトリプタミン1b受容体刺激剤 - Google Patents

皮膚および/または毛の修復のための5−ヒドロキシトリプタミン1b受容体刺激剤 Download PDF

Info

Publication number
JP2019524723A
JP2019524723A JP2019501427A JP2019501427A JP2019524723A JP 2019524723 A JP2019524723 A JP 2019524723A JP 2019501427 A JP2019501427 A JP 2019501427A JP 2019501427 A JP2019501427 A JP 2019501427A JP 2019524723 A JP2019524723 A JP 2019524723A
Authority
JP
Japan
Prior art keywords
skin
hair
vortioxetine
subject
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019501427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524723A5 (cg-RX-API-DMAC7.html
Inventor
ラファエル、ガイヤール
ファブリス、ブルーノ、クレティアン
ピエール、ロシュトー
ニコラス、トルノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Paris Descartes
Centre Hospitalier Sainte-Anne
Original Assignee
Université Paris Descartes
Centre Hospitalier Sainte-Anne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Paris Descartes, Centre Hospitalier Sainte-Anne filed Critical Université Paris Descartes
Publication of JP2019524723A publication Critical patent/JP2019524723A/ja
Publication of JP2019524723A5 publication Critical patent/JP2019524723A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019501427A 2016-07-15 2017-07-13 皮膚および/または毛の修復のための5−ヒドロキシトリプタミン1b受容体刺激剤 Pending JP2019524723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2016/001136 2016-07-15
IB2016001136 2016-07-15
PCT/EP2017/067791 WO2018011382A1 (en) 2016-07-15 2017-07-13 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair

Publications (2)

Publication Number Publication Date
JP2019524723A true JP2019524723A (ja) 2019-09-05
JP2019524723A5 JP2019524723A5 (cg-RX-API-DMAC7.html) 2020-08-20

Family

ID=56787641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019501427A Pending JP2019524723A (ja) 2016-07-15 2017-07-13 皮膚および/または毛の修復のための5−ヒドロキシトリプタミン1b受容体刺激剤

Country Status (10)

Country Link
US (1) US20190290641A1 (cg-RX-API-DMAC7.html)
EP (1) EP3484462B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019524723A (cg-RX-API-DMAC7.html)
KR (1) KR20190038840A (cg-RX-API-DMAC7.html)
CN (1) CN110022869A (cg-RX-API-DMAC7.html)
AU (1) AU2017295038B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000706A8 (cg-RX-API-DMAC7.html)
CA (1) CA3030054A1 (cg-RX-API-DMAC7.html)
MX (1) MX386989B (cg-RX-API-DMAC7.html)
WO (1) WO2018011382A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3799873A1 (en) 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
BR112020026099A2 (pt) * 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009545522A (ja) * 2006-06-22 2009-12-24 ラモット アット テル アビブ ユニバーシティ, リミテッド 末梢系限定的活性を有する薬としての新規なセロトニン再取り込み阻害剤
US20100092454A1 (en) * 2006-12-22 2010-04-15 Enrico De Vivo novel use of antidepressant compounds and related compositions
US20150005318A1 (en) * 2006-06-16 2015-01-01 H. Lundbeck A/S 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
US9399039B1 (en) * 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63203625A (ja) 1987-02-19 1988-08-23 Kao Corp 5α−リダクタ−ゼ阻害剤
FR2739553B1 (fr) 1995-10-06 1998-01-02 Oreal Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2758263B1 (fr) * 1997-01-16 1999-12-17 Oreal Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
ES2147538B1 (es) 1999-01-29 2001-04-01 Revlon Consumer Prod Corp Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
JP3441665B2 (ja) 1999-02-04 2003-09-02 株式会社資生堂 (2−置換オキシフェニル)アルカンアミド誘導体及び養毛剤、皮膚外用剤
US20060052405A1 (en) 2000-07-19 2006-03-09 Knowles W R Hair loss prevention
FR2812192B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
ATE316387T1 (de) * 2000-09-22 2006-02-15 Perlei Medical Produkte Gmbh Verwendung von antifibrinolytika für die präparation und herstellung von tupfern, kompressen oder pflaster
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
EP1435899B1 (en) 2001-09-28 2009-03-11 LG Household &amp; Health Care Ltd. A composition for promoting hair growth
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6860042B2 (en) 2002-07-19 2005-03-01 Walker-Dawson Interests, Inc. Excavation system employing a jet pump
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ATE407724T1 (de) 2002-11-12 2008-09-15 Warner Lambert Co Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
CA2511089A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
ES2436524T3 (es) 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US20050118282A1 (en) 2003-09-16 2005-06-02 Aphios Corporation Compositions and methods for inhibiting 5-alpha reductase
AR041407A1 (es) 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
US20060009430A1 (en) 2004-07-01 2006-01-12 Kelly Gregory J Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone
MXPA06015169A (es) 2004-07-08 2007-08-21 Warner Lambert Co Moduladores de androgenos.
DE202006007482U1 (de) 2006-05-10 2006-07-20 Sentner, Thomas Leuchtmöbel
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008084286A2 (en) * 2006-10-25 2008-07-17 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
ITTO20060918A1 (it) * 2006-12-22 2008-06-23 Chiara Cesano Composizione cosmetica e farmaceutica e mezzo di coltura per la rigenerazione del tessuto cutaneo, e relativi usi
EP2490669B1 (en) * 2009-10-23 2017-01-11 Fortuderm Ltd. Triptans for the treatment of psoriasis
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
CN104736176B (zh) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005318A1 (en) * 2006-06-16 2015-01-01 H. Lundbeck A/S 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
JP2009545522A (ja) * 2006-06-22 2009-12-24 ラモット アット テル アビブ ユニバーシティ, リミテッド 末梢系限定的活性を有する薬としての新規なセロトニン再取り込み阻害剤
US20100092454A1 (en) * 2006-12-22 2010-04-15 Enrico De Vivo novel use of antidepressant compounds and related compositions
US9399039B1 (en) * 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEX MALININ; BENJAMIN OSHRINE; VICTOR SEREBRUANY: "TREATMENT WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR ENHANCING WOUND HEALING", MEDICAL HYPOTHESES, vol. VOL:63, NR:1, JPN5019006280, 2004, US, pages 103 - 109, ISSN: 0004887289 *
PHARMACOLOGY & THERAPEUTICS, 2015, VOL.145, PP.43-57, JPN6021024603, ISSN: 0004710770 *

Also Published As

Publication number Publication date
AU2017295038B2 (en) 2022-09-22
BR112019000706A8 (pt) 2022-12-06
EP3484462B1 (en) 2022-12-14
KR20190038840A (ko) 2019-04-09
EP3484462A1 (en) 2019-05-22
AU2017295038A1 (en) 2019-01-24
CA3030054A1 (en) 2018-01-18
US20190290641A1 (en) 2019-09-26
MX386989B (es) 2025-03-19
BR112019000706A2 (pt) 2019-05-07
WO2018011382A1 (en) 2018-01-18
MX2019000600A (es) 2019-06-13
CN110022869A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
EP3484462B1 (en) 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
TW201240662A (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
CA2761732C (en) Composition for preventing hair loss or for stimulating hair growth
JP2008156349A (ja) 加齢の徴候を処置するためのプロビタミンa活性を有する少なくとも1種のカロチノイドとプロビタミンa活性を有さない少なくとも1種のカロチノイドの組合せ物の使用
JP6847946B2 (ja) イン・ビボ生着能増強用5−ヒドロキシトリプタミン1b受容体刺激剤
JP2008509900A (ja) 選択的ノルアドレナリン再取込阻害剤およびpdev阻害剤の配合物
JP2008509900A6 (ja) 選択的ノルアドレナリン再取込阻害剤およびpdev阻害剤の配合物
JP2025529453A (ja) 皺皮および皺の外観を軽減するために低分子の化学化合物を使用する方法
CA2339996C (en) Method for treating hot flashes in humans
KR20130028693A (ko) Pde5 억제제를 함유하는 피부 주름 개선용 조성물
JP6577581B2 (ja) Abh抗原の発現を調節する物質を含む組成物
CA2824996A1 (en) Compounds and methods for enhancing hair growth
AU2017382845B2 (en) Methods of treating hyperpigmentation disorders
CN120659603A (zh) 用于治疗肠痛或腹痛的诺卡酮
KR20250057394A (ko) 티몰 에스테르계 화합물을 포함하는 피부노화 예방 또는 개선용 조성물
KR102723050B1 (ko) Bcl-2 억제제를 포함하는 항노화 및 피부 미백용 조성물
WO2007120606A2 (en) Methods for modulating formation and progression of cellulite
JP5438239B1 (ja) シコニン誘導体を有するペリオスチンの発現抑制剤
HK1256597A1 (zh) 含有细胞老化抑制剂作为有效成分的皮肤皱纹改善用及皮肤损伤炎症疾病治疗用组合物
FR2811897A1 (fr) UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
MX2007002790A (es) Combinacion de un agonista del receptor 5-hidroxitriptamina (i) y un ligando alfa-2-delta para el tratamiento de migrana.
KR20230154641A (ko) 설포라판을 유효성분으로 포함하는 피부 질환의 예방, 개선 또는 치료용 조성물
WO2016159351A1 (ja) 涙腺ドラッグデリバリーシステム
KR20150068800A (ko) 모발 성장 촉진용 조성물
WO2011104568A1 (en) Treatment of oxidative stress disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221004

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20221019